Neuronetics, Inc. STIM

What this company does

Neuronetics, Inc. sells the NeuroStar Advanced Therapy System and associated treatment sessions to customers, and operates Greenbrook treatment centers across the United States that offer NeuroStar Advanced Therapy. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive, non-systemic, office-based treatment that uses transcranial magnetic stimulation to create a pulsed, magnetic resonance imaging-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the FDA to treat adult patients with major depressive disorder who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and is also cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with major depressive disorder. It generated revenues of $149.2 million for the year ended December 31, 2025. Through December 31, 2025, an estimated 237,574 patients had been treated worldwide, with over 8.5 million of its treatment sessions delivered. As of December 31, 2025, it had 658 full-time employees working across its sales and customer support team, research and development, operations, and general and administrative functions. Greenbrook is a wholly owned subsidiary of the Company. Neuronetics, Inc. was incorporated in Delaware in April 2003.

Written from the business description in Neuronetics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 17 March 2026. Every sentence was checked against that document before publication.